COX2 induction: a mechanism of endocrine breast cancer resistance?

COX2 induction: a mechanism of endocrine breast cancer resistance? Breast Cancer Res Treat (2017) 165:383–389 DOI 10.1007/s10549-017-4284-7 CLINICAL TRIAL COX2 induction: a mechanism of endocrine breast cancer resistance? 1 2 1,3 • • Brandi L. Clark Michael A. Murphy Landry K. Kamdem Received: 1 April 2017 / Accepted: 4 May 2017 / Published online: 21 June 2017 Springer Science+Business Media New York 2017 Abstract administration. We found no statistically significant cor- Purpose Urine prostaglandin E2 (PGE2) levels have relations between fold increase in urine PGE2 levels and shown to be a risk factor of breast cancer, and the use of the pharmacokinetics of either exemestane or 17-hy- nonsteroidal anti-inflammatory drugs (NSAIDs) is known droexemestane (major in vivo metabolite of exemestane). to be beneficial in preventing breast cancer risk and/or Conclusion Our results indicate that one of the pharma- recurrence with or without aromatase inhibitors. We cological effects to aromatase inhibitors (e.g., exemestane) hypothesized that the use of an aromatase inhibitor triggers involves the activation of the inflammatory pathway via the activation of the inflammatory pathway via release of release of PGE2. Further in vitro mechanistic and in vivo PGE2. translational studies designed to elucidate the role of this Methods A single oral 25 mg dose of an aromatase http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

COX2 induction: a mechanism of endocrine breast cancer resistance?

Loading next page...
 
/lp/springer_journal/cox2-induction-a-mechanism-of-endocrine-breast-cancer-resistance-rINt3o6RPW
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media New York
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4284-7
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2017) 165:383–389 DOI 10.1007/s10549-017-4284-7 CLINICAL TRIAL COX2 induction: a mechanism of endocrine breast cancer resistance? 1 2 1,3 • • Brandi L. Clark Michael A. Murphy Landry K. Kamdem Received: 1 April 2017 / Accepted: 4 May 2017 / Published online: 21 June 2017 Springer Science+Business Media New York 2017 Abstract administration. We found no statistically significant cor- Purpose Urine prostaglandin E2 (PGE2) levels have relations between fold increase in urine PGE2 levels and shown to be a risk factor of breast cancer, and the use of the pharmacokinetics of either exemestane or 17-hy- nonsteroidal anti-inflammatory drugs (NSAIDs) is known droexemestane (major in vivo metabolite of exemestane). to be beneficial in preventing breast cancer risk and/or Conclusion Our results indicate that one of the pharma- recurrence with or without aromatase inhibitors. We cological effects to aromatase inhibitors (e.g., exemestane) hypothesized that the use of an aromatase inhibitor triggers involves the activation of the inflammatory pathway via the activation of the inflammatory pathway via release of release of PGE2. Further in vitro mechanistic and in vivo PGE2. translational studies designed to elucidate the role of this Methods A single oral 25 mg dose of an aromatase

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Jun 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off